Healthcare Services

CD20 Antibody Market Developments and Growth Opportunities Across 2026–2030

March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The CD20 Antibody Market From 2026 To 2030?

The cd20 antibody market size has experienced rapid growth in recent years. It is anticipated to increase from $10.96 billion in 2025 to $12.08 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.2%. This historical expansion can be ascribed to factors such as the rising prevalence of b-cell related cancers, broader adoption of monoclonal antibody therapies, enhanced clinical validation of cd20 targeting, the expansion of oncology treatment protocols, and the availability of advanced biologics manufacturing.

The cd20 antibody market is projected to experience robust expansion over the coming years, with its valuation anticipated to reach $17.63 billion by 2030, progressing at a compound annual growth rate (CAGR) of 9.9%. This projected growth stems from factors such as heightened research into advanced cd20 antibodies, a surging need for targeted immunotherapies, the broadening scope of autoimmune disease treatments, a rise in biosimilar antibody approvals, and increasing capital directed towards biologic drug development. Key trends during this period are expected to encompass the wider application of next-generation cd20 monoclonal antibodies, an increase in the development of biosimilar cd20 therapies, an intensified focus on refining antibody engineering, expanded clinical deployment in autoimmune disorders, and improved optimization of antibody binding efficacy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21131&type=smp

What Key Drivers Are Influencing The Growth Of The CD20 Antibody Market?

The growing occurrence of B-cell malignancies is projected to drive the expansion of the CD20 antibody market in the future. B-cell malignancies describe a rising count of cancer cases impacting B cells, which are white blood cells crucial for immune function. This trend stems from various elements including an aging demographic, genetic predispositions, environmental exposures, lifestyle choices, enhanced diagnostic methods, and alterations in the immune system. CD20 antibodies, like rituximab, are employed to specifically target and eliminate cancerous B-cells in conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, thereby improving therapeutic results. For example, in 2024, a report from the American College of Cardiology, a US-based nonprofit medical association, projected that around 80,350 individuals (comprising 45,140 males and 35,210 females), encompassing both adults and children, would receive a diagnosis of non-Hodgkin lymphoma (NHL) in 2025. Furthermore, approximately 19,390 people (11,060 males and 8,330 females) are anticipated to succumb to this cancer. Consequently, the increasing occurrence of B-cell malignancies is fueling the expansion of the CD-19 antibody market.

Which Segments Are Included In The Analysis Of The CD20 Antibody Market?

The cd20 antibody market covered in this report is segmented –

1) By Antibody Type: Monoclonal Antibodies, Biosimilar CD20 Antibodies

2) By Drug Class Or Generation: Chimeric CD20 Antibodies, Humanized CD20 Antibodies, Fully Human CD20 Antibodies

3) By Indication: Oncology, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Other B-cell Malignancies, Autoimmune Disorders, Rheumatoid Arthritis, Multiple Sclerosis, Other Indications

4) By Route Of Administration: Intravenous (IV), Subcutaneous (SC)

5) By End User: Hospitals, Specialty Oncology And Immunology Clinics, Infusion Centers

6) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab, Ocrelizumab, Ublituximab

2) By Biosimilar CD20 Antibodies: Rituximab Biosimilars, Truxima, Rixathon Or Riximyo, Ruxience, Blitzima

What Key Trends Are Influencing The Development Of The CD20 Antibody Market?

Leading companies in the CD20 antibody market are concentrating on developing advanced solutions like biosimilars. This strategic focus aims to improve the accessibility of treatments, decrease healthcare expenditures, and satisfy the growing need for cost-effective and efficient therapies for B-cell malignancies and autoimmune conditions. Biosimilars are defined as biological medical products that are highly comparable to an already approved original product, exhibiting no significant clinical differences in terms of their safety, purity, or effectiveness. For instance, in July 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, announced it had received a complete response letter (CRL) from the US Food and Drug Administration (USFDA) for its rituximab biosimilar candidate. The company also confirmed its commitment to collaborate closely with the USFDA to address and resolve all concerns within the stipulated timelines, with the goal of making the rituximab biosimilar available to patients in the United States. The rituximab biosimilar operates by targeting the CD20 protein found on the surface of B-cells, initiating a response that leads to the destruction of these abnormal or overactive B-cells.

Which Key Industry Participants Are Active In The CD20 Antibody Market?

Major companies operating in the cd20 antibody market are F Hoffmann-La Roche AG, Novartis AG, Biogen Inc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Genmab A/S, TG Therapeutics Inc, IGM Biosciences Inc, Celltrion Inc, Sandoz Group AG, Viatris Inc, Pfizer Inc, Biocon Ltd, Dr Reddy’s Laboratories Ltd, Zydus Lifesciences Ltd, Intas Pharmaceuticals Ltd, Lupin Ltd, Torrent Pharmaceuticals Ltd, Merck KGaA, Fresenius SE

Read the full cd20 antibody market report here:

https://www.thebusinessresearchcompany.com/report/cd20-antibody-global-market-report

Which Region Is Expected To Register The Fastest Growth In The CD20 Antibody Market?

North America was the largest region in the CD20 antibody market in 2025. The regions covered in the cd20 antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored CD20 Antibody Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21131&type=smp

Browse Through More Reports Similar to the Global CD20 Antibody Market 2026, By The Business Research Company

C X C Chemokine Receptor 4 Cxcr4 Antagonists Global Market Report

https://www.thebusinessresearchcompany.com/report/c-x-c-chemokine-receptor-4-cxcr4-antagonists-global-market-report

Chemoinformatics Global Market Report

https://www.thebusinessresearchcompany.com/report/chemoinformatics-global-market-report

Peptide Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795